Last reviewed · How we verify
8-methoxypsoralen — Competitive Intelligence Brief
phase 3
Psoralen photosensitizer
DNA (non-specific intercalating agent)
Oncology; Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
8-methoxypsoralen (8-methoxypsoralen) — Medical University of Graz. 8-methoxypsoralen is a photoactive compound that intercalates into DNA and forms covalent crosslinks upon UVA exposure, triggering apoptosis in abnormal cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 8-methoxypsoralen TARGET | 8-methoxypsoralen | Medical University of Graz | phase 3 | Psoralen photosensitizer | DNA (non-specific intercalating agent) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Psoralen photosensitizer class)
- Medical University of Graz · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 8-methoxypsoralen CI watch — RSS
- 8-methoxypsoralen CI watch — Atom
- 8-methoxypsoralen CI watch — JSON
- 8-methoxypsoralen alone — RSS
- Whole Psoralen photosensitizer class — RSS
Cite this brief
Drug Landscape (2026). 8-methoxypsoralen — Competitive Intelligence Brief. https://druglandscape.com/ci/8-methoxypsoralen. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing